# Protocol Completion/Closure

After logging in, select Human Ethics from the Products drop-down. () Home - USM × × M Inbox (11) - tina.aubut@maine.e× 🖪 University of Maine System - Ca × 🔤 Human Ethics - Cayuse Researci × 🕂 ð - $\leftarrow$  $\rightarrow$  C C ○ A ब https://usm-maine-t.cayuse.com/rs/irb/#dashboard ជ  $\bigtriangledown$  $\equiv$ cayuse 10 Human Ethics Role: Reviewer 💌 Products 🔻 🛔 Tina Aubut 🛛 🔻 Dashboard Studies Submissions Tasks Meetings Reporting More Home Human Ethics + New Study

Make sure Researcher is selected under the Role drop-down. Click on highlighted protocol , New Submission button.

Dashboard	Studies	Submissions	Tasks	Meetings	Reporting	More	
IRB-2023-58	June 9th Test- Ini	itial	Approved	Rocco Researc	her N/A	N/A	06-09-2023
IRB-2023-57	June 8th Test Init	ial	Approved	Rocco Researc	N/A	N/A	06-08-2023

<u>lies</u> / Study Details						+ New Submission
	Study Deta	ils			Submissior	Renewal
						Modification
pproved						Closure
Dashboard	Studies	Submissions	Tasks	Meetings	Reporting	
Closure						
ections	<					
Project Closure						
		Project	Closure			
		* Closing S	tudy			
		Do you wi	sh to close this st	udy?		
			Vec			

Cayuse is a smart form, you may not have to answer all these questions. It depends on your responses.

For the screenshots we clicked on all possibilities.

* Closing Study											
Do you wish to clo	Do you wish to close this study?										
Yes	Reaso	n for	study	/ Clos	ure:						
	В	I	U	÷	:=	1	C-D				

# IRB Oversight Arrangements

Indicate how IRB oversight is organized for this study. This should match what is in the latest approved version of this study (latest approved Modification or Initial approval).

- O Study involving 1 site where this site is the <u>Reviewing IRB</u> (IRB of Record)
- O Study involving more than 1 site where each site will conduct their own IRB review
- O Study involving more than 1 site where this site is the Reviewing IRB (IRB of Record) for other sites
- O Study involving more than 1 site where this site is Relying on an External IRB
- O Multi-site study (multiple US sites participating in a research study using the same protocol) where this site is the Reviewing IRB (IRB of Record) for all sites
- O Multi-site study (multiple US sites participating in a research study using the same protocol) where this site is Relying on an External IRB

#### **Reviewing IRB Closure Letter**

Please upload documentation from the Reviewing IRB approving the closure of the study or this site.

ATTACH



# Enrollment

For intervention/interaction studies or aims, Enrollment includes subjects who gave consent to participate, either in writing, orally, or by voluntary completion of a survey or participation in a focus group.										
For data or specimen studies or aims, Enrollment includes subjects whose identifiable records/specimens have been reviewed.										
* Total subjects enrolled to date <u>at all sites</u>										
* Total subjects enrolled to date <u>at this institution</u>										
* Total subjects enrolled <u>at this institution</u> since the last Renewal (or since Initial approval if no Renewals)										
* Total number of withdrawals <u>at this institution</u> since start of the study <u>NOTE</u> : Includes subjects who consented but were determined ineligible, left voluntarily, or were withdrawn by study investigators.										
<ul> <li>* Have there been any withdrawals <u>at this institution</u> during the this approval period?         <ul> <li><u>NOTE</u>: Includes subjects who consented but were determined ineligible, left voluntarily, or were withdrawn by study investigators.</li> <li>Yes                 * Number of withdrawals this approval period</li> </ul> </li> </ul>										
* Briefly explain the reason for each withdrawal. B $I \ \sqcup \ \Im \ :\equiv \ :\equiv \ \odot$										

# Complaints

Have there been any subject complaints during this approval period?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites (be sure to reference the site name).

Yes	Descr	ibe a	ny suł	oject	compl	laints	d if the subject withdrew from the study as a result.	
	В	I	U	÷	:=	2	20	

# Modifications Have there been any changes to the study during this approval period that you have NOT already submitted as a Modification? Please address for <u>this institution</u> only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites. Yes Please create and submit a Modification with these changes immediately. No

# **Reportable Events**

This includes adverse events or protocol deviations that were required to promptly be submitted as an Incident per IRB Policy.

# \* Have any <u>Reportable Events</u> occurred during this approval period?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites (be sure to reference the site name).

# Yes Please briefly describe the events.

B I <u>U</u> 5- :≡ :≡ c⊃

### \* Have all Reportable Events during this approval period already been submitted as Incidents?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites.

YesNo

## Please create and submit Incident submissions for these reportable events immediately.

# Unreportable Events

This includes adverse events or protocol deviations that weren't required to promptly be submitted as an Incident per IRB Policy.

#### \* Have any Unreportable Events occurred during this approval period?

YesNo

\* Provide a list of the unreportable events that occurred at this institution, including enough information to understand why the events were determined to be unreportable.

## B I <u>U</u> 5- :≣ ;≣ c-⊃

\* As applicable, provide a list of the unreportable events that occurred <u>across the whole study at all sites</u>, including enough information to understand why the events were determined to be unreportable.

This would ONLY be applicable for studies where we are the Reviewing IRB OR multi-site clinical trials (regardless of who is the IRB of Record).

В	I	<u>U</u>	÷	:=	12	сэ

Unreportable Events Documentation

Attach any applicable documents for these unreportable events (e.g., event tracker). -Word or pdf copies are best. Links, such as Google or SharePoint, cannot be accessed by external reviewers.

ATTACH

#### New Information

Is there any <u>New Information</u> to report for this study?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, entries should include all sites (be sure to reference the site name).

For example:

- Change in funding
- Publications or scientific findings relevant to the risks and benefits to subjects
- Independent Monitor/DSMB/DSMC findings
- Interim analysis

Yes *	Pleas	e des	cribe.				
	В	I	U	÷	:=	1 2	භ 

# \* Is this Closure being submitted AFTER the <u>Study Expiration Date</u> has already passed?

This is applicable ONLY to studies that have a Study Expiration Date (e.g., full board studies and some expedited studies), NOT studies that have an Admin Check-in Date .

Yes

#### Reason for Expiration

Please explain why the study was allowed to expire (e.g., delay of renewal submission, outstanding information request, delayed documentation from IRB of Record, etc.).

B I <u>U</u> 5- :≣ :≣ co

# Final Progress Report

Please upload the final progress report, if applicable.

-Word or pdf copies are best. Links, such as Google or SharePoint, cannot be accessed by external reviewers.



# Additional Information

#### Additional Information or Comments

Summary of findings or provide additional information that you think to be beneficial to review of this Closure.

B I <u>U</u> -⊱ :≣ ≟≣ ⊂⊃

# Additional Documentation

If you have any additional documentation to provide for this Closure, upload it here. -Word or pdf copies are best. Links, such as Google or SharePoint, cannot be accessed by external reviewers.

ATTACH

When done, click Complete Submission. Pop-ups will ask you to confirm.



Certify submission: The primary PI is the only one who can certify the submission.

When all certification routing is done, it goes into the que of an ORIO analyst for next steps.

Awaiting Certification Initial IRB-2023-16 - Test View P	Research Project in Cayuse				Routing: Return Certify
PI: Tina Aubut Review Type: N/A Approvals T:	Current Analyst: N/A Review Board: N/A ask History Attachments	Decision: N/A Meeting Date: N/A	Policy: Post-2018 Rule	Required Tasks: N/A	
Research Team	Role		Result		Date
Tina Aubut	Principal Investi	gator	Pending	Certification	